How to prevent and cure COVID-19? – Online Conference
The quest for vaccines: an unprecedented rally
How to reconcile speed, efficacy and safety?
Who should pay for what?
Therapeutic antibodies vs. vaccines: do we need both?
European strengths and weaknesses
![Mathias Dewatripont, nouveau directeur pose pour Connect.](https://i3health.eu/wp-content/uploads/2020/02/Dewatripont-150x150.jpg)
Mathias Dewatripont
Co-director of the I3h Institute (ULB)
Former Vice-Governor of the National Bank of Belgium
![nathaliegarcon](https://i3health.eu/wp-content/uploads/2020/07/nathaliegarcon-150x150.jpg)
Nathalie Garçon
CEO, Bioaster, France
![Michel Goldman](https://i3health.eu/wp-content/uploads/2020/03/Michel-Goldman-150x150.jpg)
Michel Goldman
Co-director of the I3h Institute
Former Executive Director of the Innovative Medicines Initiative
![Michel Kazatchkine](https://i3health.eu/wp-content/uploads/2020/03/Michel-Kazatchkine-150x150.png)
Michel Kazatchkine
Senior Fellow, Graduate Institute for International and Development Studies, Geneva
Former Executive Director of the Global Fund against HIV, Malaria and Tuberculosis
![paul-henri-lambert](https://i3health.eu/wp-content/uploads/2020/07/paul-henri-lambert-150x150.jpg)
Paul-Henri Lambert
Professor at the Center of Vaccinology of the University of Geneva
Former Chief of Vaccines Research and Development at WHO
![Ellen ‘t Hoen](https://i3health.eu/wp-content/uploads/2020/02/Ellen-t-Hoen-150x150.jpg)
Ellen ‘t Hoen
Director of Medicine Law and Policy and Founder of the Medicines Patent Pool
![Rino-Rappuoli](https://i3health.eu/wp-content/uploads/2020/07/Rino-Rappuoli-150x150.jpg)
Rino Rappuoli
Chief Scientist & Head of external R&D, GSK Vaccines